Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

At St. Clair Health, a community health system in Pittsburgh, where Dr. Pray was working to build up an organized heart ...

Understanding the signs of ATTR-CM and advocating for early testing can be life-saving. Here's what you need to ...

Shares of Intellia Therapeutics Inc. (NTLA) plunged 24% on Thursday morning after the company said that a patient in one of ...

This comes at a challenging time for gene therapies, as multiple serious AEs and fatalities have been recently reported.

Despite scientific advances in cardiovascular care, people living in rural areas and other communities with long-term ...

While an adverse event reported in Intellia’s gene therapy trial was a “non-concern” for analysts, it follows a handful of ...

Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment ...

Shares in US biotech Intellia Therapeutics (Nasdaq: NTLA) slid by a quarter on Thursday following a safety update from its ...